BT Slingsby

BT is Founder and Managing Partner with Catalys Pacific. He served as founding CEO of Pathalys during its creation and early stages of incubation. He founded Catalys Pacific to transform life-sciences innovation in Japan using transpacific bioventure. BT is a physician-scientist and biotechnology entrepreneur leading the company creation efforts for the firm. Prior to Catalys Pacific, he founded the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries.

BT graduated from Brown University with honors, earned his MPH. and Ph.D. from Kyoto University and the University of Tokyo, and received his MD with honors from George Washington University. In recognition of his contributions to global health, he has been awarded a Foreign Ministry Commendation from the Government of Japan. BT has authored over 50 peer-reviewed articles on medicine and public health and currently is a visiting professor at the Graduate School of Medicine at the University of Tokyo, Kyoto University, and Osaka University.